Biocryst Pharmaceuticals reported $510.54M in Assets for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Assets Change
DBV Technologies DBVT:US 284.98M 167.4M
Alnylam Pharmaceuticals ALNY:US $ 3330.42M 103.13M
Biocryst Pharmaceuticals BCRX:US $ 510.54M 17.18M
Chemocentryx CCXI:US $ 419.39M 21.06M
Chugai Pharma 4519:JP Y 1625604M 40656M
Daiichi Sankyo 4568:JP Y 2294549M 73147M
Enanta Pharmaceuticals ENTA:US $ 385.21M 21.6M
Gilead Sciences GILD:US $ 62870M 210M
Glaxosmithkline GSK:US $ 89045M 644M
GlaxoSmithKline GSK:LN 8904500M 64400M
Intra Cellular Therapies ITCI:US $ 811.91M 56.67M
IONIS PHARMACEUT IONS:US $ 2456.13M 62.96M
Karyopharm Therapeutics KPTI:US $ 256.48M 37.56M
Mirati Therapeutics MRTX:US $ 1279.79M 141.51M
Neurocrine Biosciences NBIX:US $ 2005.7M 138.8M
Novavax NVAX:US $ 2622.99M 211.88M
Ptc Therapeutics PTCT:US $ 1804.06M 4.47M
Regeneron Pharmaceuticals REGN:US $ 27205.8M 857.1M
Sarepta Therapeutics SRPT:US $ 2996.85M 59.3M
Ultragenyx Pharmaceutical RARE:US $ 1320.63M 63.4M
Vertex Pharmaceuticals VRTX:US $ 15582.2M 1326.1M
YTE INCY:US $ 5319.04M 264.81M